From The Editor

1. Antibody-Drug Conjugates: Increasing Investment In R&D And Partnerhip 2/1/2023

   DeciBio’s Antibody-Drug Conjugates 2023 Industry Survey points to progress in ADC development. Respondents anticipate lower regulatory, financial, and R&D barriers as the technology matures. Senior Life Science Expert Joe Daccache, Ph.D. gave us an insider's look at the numbers.

2. What's True Of Mice ≠ What's True Of Men 1/27/2023

   After losing his mother to pancreatic cancer, entrepreneur Alex Blyth launched an immuno-oncology company that’s developing a novel allogeneic cell therapy. The company, LIfT BioSciences, recently received a shot in the arm when it was accepted into Johnson & Johnson Innovation’s JLABS network.

3. Can JP Morgan Help San Francisco? 1/25/2023

   My first in-person JP Morgan Healthcare Conference was great for business. It also left me wondering what the world's toniest healthcare conference is doing for the health of its ailing host city.

4. A Personal Case For Drug Repurposing 1/20/2023

   Amidst the dealmaking and spectacle of the 41st Annual JP Morgan Healthcare Conference, a bright and personal light was cast on the value of a different kind of collaboration: drug repurposing. There’s a deep vein of patient benefit sitting on pharmacy shelves, and Michael Fajgenbaum, M.D. wants to tap it. 

5. 60 Minutes To IND Success 1/6/2023

   On 1/24/23, Daniela Drago, Ph.D. and Kati Abraham will join us for the discussion, IND Success: Navigate Through The Regulatory Gray, and I hope you do, too. We’ll talk through reasons for clinical holds, offer tips for avoiding and addressing them, and share best practices on ensuring smooth submissions on your journey from development to the clinic.

6. Big Bio Breeds Startup Leadership 12/27/2022

   Richard Francis’ arrival at Purespring in 2021 was indicative of a longer-term trend in the biopharma space that’s inciting a bit of a talent exodus from Big Pharma to emerging bio. While he's now returning to his big pharma generics roots, here's what he looked for in a startup leadership opportunity.

7. Snake Oil Or Slippery CEO? 12/22/2022

   Nader Pourhassan was just charged with a whole bunch of crimes. At the nucleus of the charges sits Pourhassan’s overzealous—and as it turns out, illegal—oversell of leronlimab, the monoclonal antibody he hyped as an HIV and COVID-19 therapeutic panacea when he was CEO at Cytodyn.

8. Inside The Altavant/Enzyvant Self-Made Merger 12/21/2022

   Prior to their merger, Enzyvant and Altavant didn’t have much in common beyond their suffix and their CEO. That CEO is Bill Symonds, Pharm.D., the architect of the merger whose history with the "vants" runs deep. Here, Dr. Symonds shares the company’s strategy and the implications of the combination. 

9. From Racecars To Regenerative Medicine 12/14/2022

   Find out what inspired a mechanical engineer, a U.S. Marine veteran, and a racecar driver to launch a regenerative medicine company manufacturing perinatal tissue allografts and get its products to market at breakneck speed.

10. Data Confidence Drives Clinical, Financial Perseverance 12/7/2022

    Under the leadership of Mai-Britt Zocca, Ph.D., IO Biotech raised a $150 million Series B during a pandemic to move forward with a target that's seen its fair share of failure. To get there, the clinical stage biopharma leaned hard into its data differentiators.